Yuxian Bai Selected Research

alpha-Fetoproteins (alpha-Fetoprotein)

12/2022	Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study.
1/2022	Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuxian Bai Research Topics

Disease

40	Neoplasms (Cancer) 03/2024 - 07/2010
22	Hepatocellular Carcinoma (Hepatoma) 10/2023 - 10/2013
17	Disease Progression 12/2023 - 02/2014
15	Colorectal Neoplasms (Colorectal Cancer) 04/2024 - 06/2015
15	Stomach Neoplasms (Stomach Cancer) 11/2023 - 09/2013
14	Hypertension (High Blood Pressure) 01/2023 - 06/2015
11	Esophageal Squamous Cell Carcinoma 02/2024 - 01/2019
11	Adenocarcinoma 12/2023 - 10/2014
7	Neoplasm Metastasis (Metastasis) 10/2023 - 10/2016
6	Esophageal Neoplasms (Esophageal Cancer) 11/2021 - 01/2018
5	Anemia 12/2023 - 01/2019
5	Carcinoma (Carcinomatosis) 01/2022 - 02/2014
5	Proteinuria 11/2021 - 01/2017
4	Nausea 12/2023 - 01/2019
4	Pancreatic Neoplasms (Pancreatic Cancer) 11/2023 - 11/2014
4	Liver Neoplasms (Liver Cancer) 10/2023 - 11/2017
3	Neuroendocrine Tumors (Neuroendocrine Tumor) 10/2023 - 01/2022
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2022 - 07/2010
3	Leukopenia 01/2021 - 01/2019
3	Neutropenia 01/2021 - 01/2019
2	Microsatellite Instability 03/2024 - 11/2023
2	Respiratory Insufficiency (Respiratory Failure) 01/2023 - 11/2020
2	Diarrhea 01/2022 - 08/2020
2	Cholangiocarcinoma 11/2021 - 01/2020
2	Hand-Foot Syndrome 01/2021 - 01/2019
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2020 - 01/2019
2	Exanthema (Rash) 06/2015 - 10/2014
2	Breast Neoplasms (Breast Cancer) 05/2014 - 01/2013
1	Shock 01/2023
1	Multiple Organ Failure (MODS) 01/2023
1	Pneumonia (Pneumonitis) 12/2022
1	Dyspnea (Shortness of Breath) 01/2022

Drug/Important Bio-Agent (IBA)

9	Fluorouracil (Carac)FDA LinkGeneric 01/2024 - 10/2013
9	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2024 - 10/2013
8	Biomarkers (Surrogate Marker)IBA 11/2023 - 10/2014
8	apatinibIBA 01/2023 - 09/2013
7	Sorafenib (BAY 43-9006)FDA Link 10/2023 - 01/2021
7	Capecitabine (Xeloda)FDA Link 01/2021 - 02/2014
6	HMPL-013IBA 04/2024 - 01/2017
6	Monoclonal AntibodiesIBA 01/2024 - 01/2020
6	surufatinibIBA 10/2023 - 11/2020
6	anlotinibIBA 10/2021 - 01/2019
6	Cisplatin (Platino)FDA LinkGeneric 03/2020 - 10/2014
5	pembrolizumabIBA 03/2024 - 01/2022
5	Immune Checkpoint InhibitorsIBA 11/2023 - 01/2021
5	Bevacizumab (Avastin)FDA Link 06/2023 - 01/2021
5	camrelizumabIBA 01/2023 - 01/2020
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2021 - 10/2016
5	Leucovorin (Folinic Acid)FDA Link 10/2018 - 10/2013
4	Irinotecan (Camptosar)FDA LinkGeneric 01/2024 - 08/2018
4	tislelizumabIBA 10/2023 - 01/2020
4	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2023 - 06/2015
4	Tyrosine Kinase InhibitorsIBA 01/2023 - 05/2016
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2010
4	1-phenyl-3,3-dimethyltriazene (PDT)IBA 11/2021 - 01/2018
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 11/2021 - 01/2017
3	Trastuzumab (Herceptin)FDA Link 12/2023 - 02/2016
3	sintilimabIBA 12/2023 - 01/2021
3	Alanine Transaminase (SGPT)IBA 01/2023 - 06/2015
3	lenvatinibIBA 01/2023 - 05/2021
3	human ERBB2 proteinIBA 01/2023 - 02/2016
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 02/2014
3	BilirubinIBA 11/2021 - 01/2021
3	artenimol (dihydroartemisinin)IBA 07/2019 - 01/2018
2	Gemcitabine FDA Link 11/2023 - 11/2014
2	Biosimilar PharmaceuticalsIBA 06/2023 - 01/2021
2	alpha-Fetoproteins (alpha-Fetoprotein)IBA 12/2022 - 01/2022
2	Caspase 8 (Caspase-8)IBA 01/2022 - 11/2021
2	Caspase 3 (Caspase-3)IBA 01/2022 - 11/2021
2	atezolizumabIBA 01/2022 - 07/2021
2	Photosensitizing Agents (Photosensitizers)IBA 11/2021 - 01/2021
2	ErbB Receptors (EGF Receptor)IBA 10/2021 - 10/2014
2	AcidsIBA 12/2020 - 11/2017
2	Pyruvate KinaseIBA 10/2020 - 07/2019
2	regorafenibIBA 08/2020 - 06/2015
2	Docetaxel (Taxotere)FDA Link 03/2020 - 01/2016
2	LigandsIBA 01/2020 - 01/2018
2	Cetuximab (Erbitux)FDA Link 10/2018 - 10/2014
2	artemisinin (artemisinine)IBA 01/2018 - 01/2018
2	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2014 - 10/2013
1	sugemalimabIBA 02/2024
1	PlatinumIBA 12/2023
1	nimotuzumabIBA 11/2023
1	Plasminogen Activators (Plasminogen Activator)IBA 06/2023
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 06/2023
1	Programmed Cell Death 1 ReceptorIBA 02/2023
1	NivolumabIBA 01/2023
1	RamucirumabIBA 12/2022
1	1- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA 04/2022
1	Growth Factor ReceptorsIBA 01/2022
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022
1	Sincalide FDA Link 01/2022
1	B7-H1 AntigenIBA 01/2022

Therapy/Procedure

29	Therapeutics 01/2024 - 10/2014
26	Drug Therapy (Chemotherapy) 02/2024 - 09/2013
6	Photochemotherapy (Photodynamic Therapy) 01/2022 - 11/2017
5	Immunotherapy 03/2023 - 07/2010
3	Microbubbles 01/2021 - 11/2017
1	Duration of Therapy 01/2023
1	Intravenous Infusions 01/2022